Takeda starts pan-Asian phase III study for AMG706 (2-modesanib-phosphate), a lung cancer drug, in Japan, Hong Kong, South Korea, and Taiwan

Takeda press release, July 26, 2012

Takeda starts pan-Asian phase III study for AMG706 (2-modesanib-phosphate), a lung cancer drug, in Japan, Hong Kong, South Korea, and Taiwan
Scroll to top